Loading...
Market
What percentage of major hospitals will adopt dual-drug nanoparticle therapy by 2026?
2
Resolution / Starting Odds
More than 50% of major hospitals • 25%
25% to 50% of major hospitals • 25%
Less than 25% of major hospitals • 25%
Not adopted • 25%
Surveys and reports from major healthcare systems and medical journals
Story
Researchers Unveil Dual-Drug Nanoparticle Therapy for Cancer Patients; Dostarlimab Cures Colorectal Cancer Without Chemotherapy or Surgery
Dec 24, 2024, 01:14 PM
Researchers have introduced a groundbreaking dual-drug nanoparticle therapy aimed at treating cancer patients. This innovative approach combines phototherapy with chemotherapy, potentially providing a more effective method for combating aggressive tumors while minimizing harsh side effects. The Massachusetts Institute of Technology (MIT) has been at the forefront of this research, highlighting its promise for late-stage cancer patients who typically endure severe treatment regimens. In a related development, the drug Dostarlimab has shown remarkable efficacy in clinical trials for colorectal cancer, curing all patients without the need for chemotherapy or surgery. Additionally, advancements in digital twin technology have led to a method that can revert colon cancer cells to a state resembling normal cells, further reducing side effects associated with traditional cancer treatments.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
More than 80% • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 1% • 25%
1% to 5% • 25%
5% to 10% • 25%
More than 10% • 25%
Less than 20% • 25%
20-40% • 25%
40-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%